P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

• E. Joffe,
• G. Nowakowski,
• H. Tun,
• A. Rosenthal,
• M. Lunning,
• R. Ramchandren,
• C.-C. Li,
• L. Zhou,
• E. Martinez,
• R. von Roemeling,
• R. Earhart,
• M. McMahon,
• I. Isufi,
• L. Leslie

Affiliations

E. Joffe

1 MSKCC, NY

G. Nowakowski

2 Mayo Clinic-Minnesota, Rochester, Rochester

H. Tun

3 Mayo Clinic-Florida, Jacksonville

A. Rosenthal

4 Department of Hematology, Mayo Clinic- Arizona, Phoenix

M. Lunning

5 University of Nebraska, Omaha

R. Ramchandren

6 University of Tennessee Medical Center, Knoxville

C.-C. Li

7 Curis, Lexington

L. Zhou

7 Curis, Lexington

E. Martinez

7 Curis, Lexington

R. von Roemeling

7 Curis, Lexington

R. Earhart

7 Curis, Lexington

M. McMahon

7 Curis, Lexington

I. Isufi

8 Yale New Haven Hospital, New Haven

L. Leslie

9 John Theurer Cancer Center, Hackensack, United States of America